dupilumab · Dupixent
Monoclonal antibody
Also known as REGN668
Evidence outlook
Approved: Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Prurigo Nodularis, Eosinophilic Esophagitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (7)
- Allergic Fungal Rhinosinusitis: DUPIXENT for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery
- Treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery
- Chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid
- Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils
- Treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments
- Atopic Dermatitis DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. Asthma DUPIXENT is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma. DUPIXENT is not indicated for relief of acute bronchospasm...
- Atopic dermatitis Adults and adolescents Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Children 6 months to 11 years of age Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. Asthma Adults and adolescents Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01949311 NCT01949311 · Atopic Dermatitis This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment. Its registered primary outcome on ClinicalTrials.gov is "Number of Treatment Emergent Adverse Events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT01949311 | 3 | Number of Treatment Emergent Adverse Events (TEAEs) (Up to 272 weeks); OPTIONAL SUB-STUDY: Number of Adverse Events of Special Interest (AESIs) Through the Last Study Visit After Switching to the New Dupilumab Drug Product (Up to 24 Weeks) 2022-06-27 | Number of Treatment Emergent Adverse Events (TEAEs) (Up to 272 weeks): Dupilumab 14717 Number of Events | Weak signal | link ↗ |
View 8 more trials
SOLO 1 NCT02277743 · Atopic Dermatitis The trial was randomized, triple-blind, placebo-controlled, and included 671 participants, with the clinical primary endpoint significantly favoring both dupilumab regimens: 37.9% and 37.2% achieved the specified IGA response versus 10.3% with placebo (both p<0.0001). The registry does not report a primary-endpoint power calculation, so the study is presented as moderate rather than strong evidence despite its otherwise rigorous design. Registry: NCT02277743 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 2015-11 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Week 16): Dupilumab 300 mg q2w 37.9% | Dupilumab 300 mg qw 37.2% vs Placebo 10.3% | Partial signal | link ↗ |
SOLO 2 NCT02277769 · Atopic Dermatitis The trial was randomized, triple-blind, placebo-controlled, and included 708 participants, with an objective clinical skin-severity primary endpoint. The primary endpoint was met for both dupilumab regimens, but the record does not report a power calculation needed to verify that the study was adequately powered, so the evidence is graded moderate rather than strong. Registry: NCT02277769 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 2015-10-31 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Week 16): Dupilumab 300 mg q2w 36.1% | Dupilumab 300 mg qw 36.4% vs Placebo 8.5% | Partial signal | link ↗ |
CHRONOS NCT02260986 · Atopic Dermatitis This was a randomized, triple-blind, placebo-controlled trial of 740 participants, and its clinical primary endpoint was met for both dupilumab regimens: IGA response was 38.7% with 300 mg every 2 weeks and 39.2% weekly versus 12.4% with placebo, with p<0.0001 for each comparison. The registry does not report a primary-endpoint power calculation, so the evidence is graded moderate despite the strong blinded design and statistically significant result. Registry: NCT02260986 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Baseline to Week 16) 2015-08 | Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 (Baseline to Week 16): Dupilumab 300 mg q2w 38.7% | Dupilumab 300 mg qw 39.2% vs Placebo qw 12.4% | Partial signal | link ↗ |
SOLO-CONTINUE NCT02395133 · Atopic Dermatitis This was a randomized, triple-blind, placebo-controlled trial of 422 prior responders, and both clinical primary endpoints (loss of eczema improvement and keeping a 75% eczema score improvement at week 36) were met for every dupilumab regimen against placebo. Registry: NCT02395133 | 3 | Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) (Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)); Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36 2016-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03054428 NCT03054428 · Atopic Dermatitis This was a randomized, quadruple-blind, placebo-controlled phase 3 trial in 251 adolescents, and both clinical co-primary endpoints (clear or almost clear skin and 75% improvement in eczema severity at week 16) were met for both dupilumab regimens. A power calculation called for 80 patients per group, and every group enrolled at least 82. Registry: NCT03054428 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction From Baseline of ≥2 Points) at Week 16 (Baseline and Week 16); Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (≥75% Improvement From Baseline) at Week 16 (Baseline and Week 16) 2018-04-04 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT03345914 NCT03345914 · Atopic Dermatitis This was a randomized, quadruple-blind, placebo-controlled phase 3 trial in 367 children, and its clinical primary endpoint (clear or almost clear skin at week 16) was met for both dupilumab regimens (p=0.0004 and p<0.0001). A power calculation set a target of about 330 patients, and 367 were enrolled. Registry: NCT03345914 | 3 | Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 2019-06-20 | Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4% | Reliable signal | link ↗ |
Liberty AD NCT03346434 · Atopic Dermatitis This grade covers the randomized part of the trial: 162 young children were assigned at random and double-blind to dupilumab or placebo, and both clinical primary endpoints (clear or almost clear skin and 75% improvement in eczema severity at week 16) were met with p<0.0001. A power calculation set a target of 160 children for this part, and 162 were randomized. Registry: NCT03346434 | 2/3 | Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab (Post-dose on Days 1, 3, 8, 18, and 29); Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) (Baseline up to Week 4); Part A: Number of Participants With TEAEs by Severity According to Qualitative Toxicity Scale (Baseline up to Week 4); Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16; Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16 2021-07-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT04417894 NCT04417894 · Moderate to Severe Atopic Hand and Foot Dermatitis This was a randomized, quadruple-blind, placebo-controlled trial in 133 patients, and its clinical primary endpoint (clear or almost clear hands and feet at week 16) was met, 40.3% vs 16.7% (p=0.0030). A power calculation set a target of 130 patients, and 133 were enrolled. Registry: NCT04417894 | 3 | Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 2022-08-31 | Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (46)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (51)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (57)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (22)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 4 (1)
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other IL-4R-alpha drugs
GS101, Manfidokimab, QL2108, Rademikibart, SHR-1819 and 5 more. Compare all 11 IL-4R-alpha drugs
This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Atopic Dermatitis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dupilumab (Dupixent): this drug | Approved | Monoclonal antibody | IL-4R-alpha | Weak signal | NCT04417894: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% NCT03345914: Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 (Week 16): Dupilumab 300 mg Q4W + TCS 32.8% | Dupilumab 100 mg or 200 mg Q2W + TCS 29.5% vs Placebo + TCS 11.4% | |
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | Reliable signal | NCT04345367: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) NCT03349060: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12 (Baseline, Week 12): PF-04965842 100 mg 23.7% | PF-04965842 200 mg 43.8% vs Placebo 7.9% | |
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | Reliable signal | NCT02118766: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 (Day 29): AN2728 Topical Ointment, 2 Percent 32.8% vs AN2728 Topical Ointment, Vehicle 25.4% NCT02118792: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 (Day 29): AN2728 Ointment, 2 Percent (%) 31.4% vs AN2728 Ointment, Vehicle 18% | |
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | Partial signal | NCT03908970: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36) NCT03911401: IGA success (score 0 or 1 with at least a 2-grade improvement) at week 4: difamilast 0.3% 44.6% and 1% 47.1% vs vehicle 18.1%; p<0.001 for each dose vs vehicle. n=83, 85, 83 (Saeki 2022, Br J Dermatol). | |
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT04178967: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) NCT04146363: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 43.1% (95% CI 37.1 to 49) vs Placebo 12.7% (95% CI 7 to 18.5) | |
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | Reliable signal | NCT03989349: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 37.7% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 26% NCT03985943: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population (Week 16): Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg 35.6% vs Initial Treatment Period (Baseline - Week 16 Predose): Placebo 24.6% | |
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | Reliable signal | NCT06631170: Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) NCT04773600: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 (Week 4): Roflumilast Cream 0.15% 28.9% vs Vehicle Cream 12% | |
| Ruxolitinib (Opzelura) | Approved | Small molecule | JAK1/2 | Reliable signal | NCT03745638: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) NCT03745651: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 39% (95% CI 32.6 to 45.6) | VC Period: Ruxolitinib 1.5% Cream BID 51.3% (95% CI 44.6 to 58) vs VC Period: Vehicle Cream BID 7.6% (95% CI 3.5 to 14) | |
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | Reliable signal | NCT05014568: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 45.4% vs Vehicle Cream 13.9% NCT05032859: Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. (Baseline to Week 8): Tapinarof Cream 46.4% vs Vehicle Cream 18% | |
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 | Reliable signal | NCT05958407: Percentage of Participants With IGA-AHE Score of 0 (Clear) or 1 (Almost Clear) (At Week 16): Tralokinumab 40% (95% CI 31.3 to 49.4) vs Placebo 10.6% (95% CI 5 to 20.9) | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03607422: EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). NCT03569293: EASI-75 at week 16 (Measure Up 1): 70% (196/281) upadacitinib 15mg, 80% (227/285) upadacitinib 30mg, vs 16% (46/281) placebo; adjusted difference vs placebo 53.3% [46.4-60.2] and 63.4% [57.1-69.8] respectively, both p<0.0001 | |
| ADSTEM | Phase 3 | Cell therapy | autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Asivatrep | Phase 3 | Small molecule | TRPV1 | Reliable signal | NCT02965118: IGA success (score 0 or 1) at week 8: 36.0% asivatrep vs 12.8% vehicle (P<.001) | |
| Baricitinib (Olumiant) | Phase 3 | Small molecule | JAK, JAK1/2 | Reliable signal | NCT03334422: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% NCT03334396: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib) (16 Weeks): 2 mg Baricitinib 11.4% | 4 mg Baricitinib 16.8% vs Placebo 4.8% | |
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Jaktinib (Zepuping) | Phase 3 | Small molecule | JAK1/2/3 | Partial signal | No reviewed efficacy summary in this indication | |
| LW402 | Phase 3 | Small molecule | JAK1 | Partial signal | No reviewed efficacy summary in this indication | |
| Manfidokimab | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | No reviewed efficacy summary in this indication | |
| Pumecitinib | Phase 3 | Small molecule | JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| QLM3003 | Phase 3 | Small molecule | JAK | Partial signal | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT05017480: vIGA 0/1 with a reduction of 2 points or more at week 16: rademikibart 300 mg Q2W 29.0% vs placebo 5.9%, P<0.001 (SEASIDE CHINA, Br J Dermatol 2026). | |
| Rezpegaldesleukin | Phase 3 | Protein / enzyme therapeutic | IL-2 mutein (Treg-selective) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1819 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Soficitinib (ICP-332) | Phase 3 | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| SSGJ-611 | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | Reliable signal | NCT06277765: EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) NCT05265923: EASI-75 response at week 16: 66.9% stapokibart vs 25.8% placebo (significantly higher) | |
| Telikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| VC005 | Phase 3 | Small molecule | JAK1, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zemprocitinib | Phase 3 | Small molecule | JAK1 | Reliable signal | NCT06277245: EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) | |
| Afimkibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| Barzolvolimab | Phase 2 | Monoclonal antibody | KIT | not yet graded | No reviewed efficacy summary in this indication | |
| Bempikibart | Phase 2 | Monoclonal antibody | IL-7 receptor alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BFB759 | Phase 2 | Monoclonal antibody | IL-1RAP | not yet graded | No reviewed efficacy summary in this indication | |
| Bosakitug | Phase 2 | Monoclonal antibody | TSLP | Weak signal | NCT05932654: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 (Week 26): 300 mg 94.1% (95% CI 71.3 to 99.9) | |
| Camoteskimab | Phase 2 | Monoclonal antibody | IL-18 | Partial signal | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | Weak signal | Featured results are safety only in this race | |
| CMS-D001 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ENV-294 | Phase 2 | Small molecule | — | Weak signal | Featured results are safety only in this race | |
| EVO101 | Phase 2 | Small molecule | IRAK4 | Partial signal | NCT05579899: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 (8 weeks): EVO101 Cream -43.5% (Standard Deviation 60.85) vs Vehicle Cream -62% (Standard Deviation 38.78) missed | |
| EVO301 | Phase 2 | Protein / enzyme therapeutic | IL-18 | Partial signal | NCT06723405: Placebo-adjusted improvement in EASI at Week 12: 33% (95% CI -50, -17; p<0.01) | |
| FB825 | Phase 2 | Monoclonal antibody | CεmX domain of membrane-bound IgE (mIgE) | Weak signal | No reviewed efficacy summary in this indication | |
| Felcorekibart | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Galvokimig | Phase 2 | Multispecific antibody | IL-13, IL-17A, IL-17F | Partial signal | Featured results are safety only in this race | |
| GHZ339 | Phase 2 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| GIA632 | Phase 2 | Monoclonal antibody | IL-15 | not yet graded | No reviewed efficacy summary in this indication | |
| HSK44459 | Phase 2 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| HY209gel | Phase 2 | Small molecule | GPCR19 / GPBAR1 (TGR5, bile acid receptor) | Partial signal | Featured results are safety only in this race | |
| IN-115314 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-95597528 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| JYP0061 | Phase 2 | Small molecule | JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| KT-621 | Phase 2 | Small molecule | STAT6 | Weak signal | Featured results are safety only in this race | |
| Lepzacitinib | Phase 2 | Small molecule | JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| LNK01004 | Phase 2 | Small molecule | Pan-JAK | Partial signal | Featured results are safety only in this race | |
| LT-002-158 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 2 | Antibody-derived scaffold | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Lutikizumab | Phase 2 | Multispecific antibody | IL-1α/IL-1β (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Modzatinib | Phase 2 | Small molecule | ITK and JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mosedipimod | Phase 2 | Small molecule | NF-kB / CCL26 pathway | not yet graded | No reviewed efficacy summary in this indication | |
| Nitrosomonas Eutropha (B244) | Phase 2 | Microbiome therapeutic | live biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244) | Reliable signal | NCT04490109: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) (Baseline to Day 28): B244 O.D. 5.0 -2.8 score on a scale (Standard Error 0.184) | B244 O.D. 20.0 -2.8 score on a scale (Standard Error 0.184) vs Vehicle -2.1 score on a scale (Standard Error 0.18) | |
| Olevaprubart | Phase 2 | Monoclonal antibody | OX40 | Weak signal | Featured results are safety only in this race | |
| Ompekimig | Phase 2 | Multispecific antibody | IL-4, IL-13, IL-33 | Partial signal | NCT05995964: Stage 1, high-dose ompekimig vs placebo: met the primary endpoint (EASI-75 at week 16); no ompekimig figures were given (2026-03-09). | |
| OpSCF | Phase 2 | Monoclonal antibody | Stem cell factor (SCF / KIT ligand) | Partial signal | NCT06101823: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16 (Baseline, Week 16): OpSCF 600 mg -71.476 percent change (Standard Error 8.6876) | OpSCF Matching-Placebo -50.992 percent change (Standard Error 8.8073) | |
| Orismilast | Phase 2 | Small molecule | PDE4B/D | Partial signal | NCT05469464: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 (Baseline and Week 16): Orismilast Modified Release Tablets 20 mg BID -55.1% (Standard Error 4.89) | Orismilast Modified Release Tablets 30 mg BID -52.2% (Standard Error 5.39) | Orismilast Modified Release Tablets 40 mg BID -61.4% (Standard Error 5.02) vs Placebo Tablets BID -50.4% (Standard Error 4.98) missed NCT02496546: In adults with mild to moderate atopic dermatitis treated twice daily for 3 weeks, total sign score at end of treatment was 5.2 (least squares mean 5.1) with orismilast cream 20 mg/g versus 6.2 (LS mean 6.3) with vehicle, a statistically significant difference (P = .014). | |
| PF-08049820 | Phase 2 | Small molecule | STAT6 | not yet graded | No reviewed efficacy summary in this indication | |
| PUR 0110 | Phase 2 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| QLS12010 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| XKH001 | Phase 2 | Monoclonal antibody | IL-25 | not yet graded | No reviewed efficacy summary in this indication | |
| CKD-706 | Phase 1 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Itepekimab | Discontinued | Monoclonal antibody | IL-33 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 71 furthest-along competitors are listed; 41 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(35 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dupixent (dupilumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (18)
January 2027 (2)
February 2027 (1)
What to watch
March 2027 (2)
April 2027 (2)
June 2027 (3)
July 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (5)
2028 (9)
February 2028 (2)
May 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (1)
What to watch
December 2028 (4)
What to watch
What to watch
What to watch
What to watch
2029 (2)
2031 (1)
June 2031 (1)
What to watch
2034 (1)
September 2034 (1)
What to watch
Regulatory and conference events
(9)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent